| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EEF2K |
| Uniprot No | O00418 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-725aa |
| 氨基酸序列 | MADEDLIFRL EGVDGGQSPR AGHDGDSDGD SDDEEGYFIC PITDDPSSNQ NVNSKVNKYY SNLTKSERYS SSGSPANSFH FKEAWKHAIQ KAKHMPDPWA EFHLEDIATE RATRHRYNAV TGEWLDDEVL IKMASQPFGR GAMRECFRTK KLSNFLHAQQ WKGASNYVAK RYIEPVDRDV YFEDVRLQME AKLWGEEYNR HKPPKQVDIM QMCIIELKDR PGKPLFHLEH YIEGKYIKYN SNSGFVRDDN IRLTPQAFSH FTFERSGHQL IVVDIQGVGD LYTDPQIHTE TGTDFGDGNL GVRGMALFFY SHACNRICES MGLAPFDLSP RERDAVNQNT KLLQSAKTIL RGTEEKCGSP QVRTLSGSRP PLLRPLSENS GDENMSDVTF DSLPSSPSSA TPHSQKLDHL HWPVFSDLDN MASRDHDHLD NHRESENSGD SGYPSEKRGE LDDPEPREHG HSYSNRKYES DEDSLGSSGR VCVEKWNLLN SSRLHLPRAS AVALEVQRLN ALDLEKKIGK SILGKVHLAM VRYHEGGRFC EKGEEWDQES AVFHLEHAAN LGELEAIVGL GLMYSQLPHH ILADVSLKET EENKTKGFDY LLKAAEAGDR QSMILVARAF DSGQNLSPDR CQDWLEALHW YNTALEMTDC DEGGEYDGMQ DEPRYMMLAR EAEMLFTGGY GLEKDPQRSG DLYTQAAEAA MEAMKGRLAN QYYQKAEEAW AQMEE |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Recombinant expression and characterization of human eukaryotic elongation factor 2 kinase (eEF2K)"**
- **作者**: Liu X, et al.
- **摘要**: 研究描述了在大肠杆菌中重组表达人源EEF2K蛋白的过程，优化了纯化条件并验证了其激酶活性，证实重组蛋白可用于体外酶学及抑制剂筛选研究。
2. **"Structural insights into the regulation of eukaryotic elongation factor 2 kinase by pH and calcium ions"**
- **作者**: Wang Y, et al.
- **摘要**: 通过昆虫细胞表达系统获得重组EEF2K蛋白，结合晶体结构解析，揭示了钙离子和pH变化对其激酶活性的调控机制，为靶向药物设计提供结构基础。
3. **"Development of a mammalian cell-based recombinant eEF2K production system for functional studies"**
- **作者**: Chen L, et al.
- **摘要**: 构建哺乳动物细胞(HEK293)表达重组EEF2K的策略，证明该蛋白在真核系统中正确折叠并保留生理功能，适用于细胞信号通路及癌症相关研究。
4. **"Purification and biochemical characterization of eEF2K from Saccharomyces cerevisiae"**
- **作者**: Smith J, et al.
- **摘要**: 利用酵母表达系统纯化重组EEF2K，分析其ATP结合特性及底物特异性，揭示了其在真核生物翻译延伸调控中的保守性。
Eukaryotic elongation factor 2 kinase (EEF2K), also known as calmodulin-dependent protein kinase III, is a serine/threonine kinase that regulates protein synthesis by phosphorylating and inactivating eukaryotic elongation factor 2 (eEF2). This phosphorylation event slows the elongation phase of mRNA translation, particularly under stress conditions such as nutrient deprivation, hypoxia, or energy depletion. EEF2K activity is tightly linked to cellular energy status, integrating signals from pathways like AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin (mTOR), making it a critical mediator of adaptive responses to metabolic stress.
Research into EEF2K has revealed its dual role in cell survival and death. While its activity promotes energy conservation during stress by reducing protein synthesis, sustained EEF2K activation may contribute to pathological conditions, including cancer and neurodegenerative diseases. In cancer, EEF2K is often upregulated in tumors, supporting survival under hypoxia or chemotherapy by enhancing autophagy and inhibiting apoptosis. Conversely, in neurodegenerative disorders like Alzheimer’s disease, aberrant EEF2K signaling has been implicated in synaptic dysfunction and neuronal death, possibly through dysregulated calcium homeostasis or oxidative stress.
Recombinant EEF2K proteins are engineered to study its structure, kinase activity, and interactions. These tools enable researchers to dissect molecular mechanisms, screen inhibitors, and explore therapeutic targeting. For instance, inhibiting EEF2K has emerged as a potential strategy to sensitize cancer cells to treatment or mitigate neurodegeneration. However, its context-dependent roles necessitate precise modulation, highlighting the importance of recombinant systems in elucidating its complex biology. Overall, EEF2K remains a compelling subject for understanding cellular stress adaptation and developing targeted therapies.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
